-

03:24:52 PM

RANI Stock News

RANI - Rani Therapeutics Holdings Inc

09/18/23 8:00 AM

Nasdaq : RANI

clinical triallow float

Rani Therapeutics Initiates Phase 1 Study of RT-111 (RaniPill® Containing Ustekinumab Biosimilar, CT-P43)

Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a

RHEA-AI

positive

09/07/23 4:05 PM

Nasdaq : RANI

clinical triallow float

Rani Therapeutics Announces Successful Drug Delivery of High-Capacity Pill in Preclinical Studies

- Two preclinical studies of RaniPill ® HC achieved 18/20 successful drug delivery of orally administered teriparatide resulting in a cumulative 90% success rate - Rani will continue preclinical testing to confirm preliminary reliability rate and optimize device performance - Increased payload of

RHEA-AI

very positive

09/06/23 8:00 AM

Nasdaq : RANI

conferenceslow float

Rani Therapeutics to Participate in September Investor Conferences

Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that Rani will participate in and present at two

RHEA-AI

neutral

08/11/23 4:05 PM

Nasdaq : RANI

earningslow float

Rani Therapeutics Reports Second Quarter 2023 Financial Results; Provides Corporate Update

- Expansion of partnership with Celltrion for development of RT-105 to complement existing partnership for RT-111 - Appointment of Kate McKinley as Chief Business Officer - Presentation of three abstracts on RT-102 and RT-112 at the Endocrine Society Annual Conference and selection as winner of

RHEA-AI

positive

08/04/23 4:05 PM

Nasdaq : RANI

conferenceslow float

Rani Therapeutics to Participate in August Investor Conferences

Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that the Company will participate in three upcoming

RHEA-AI

neutral

06/21/23 8:00 AM

Nasdaq : RANI

low float

Rani Therapeutics’ Presentation On Oral Delivery of PTH for Osteoporosis Named Presidential Poster Competition Winner at ENDO 2023 Annual Conference

Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, announced that its abstract entitled “An Orally Administered Robotic

RHEA-AI

neutral

06/08/23 8:00 AM

Nasdaq : RANI

low float

Rani Therapeutics Announces Acceptance of Late-Breaking Abstract of Oral Delivery of GLP-1 Agonist at the American Diabetes Association Annual Conference

Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that a late-breaking abstract “Oral Delivery of a

RHEA-AI

neutral

06/05/23 8:00 AM

Nasdaq : RANI

partnershiplow float

Rani Therapeutics and Celltrion Expand Partnership to Include Adalimumab Biosimilar for RT-105

Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a

RHEA-AI

very positive

06/01/23 8:00 AM

Nasdaq : RANI

conferenceslow float

Rani Therapeutics to Present at the Jefferies Healthcare Conference

Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced the company’s Chief Executive Officer, Talat Imran,

RHEA-AI

neutral

05/31/23 8:00 AM

Nasdaq : RANI

low float

Rani Therapeutics Announces Acceptance of Three Abstracts for Presentation at ENDO 2023 Annual Conference

Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that three submitted abstracts were accepted for poster

RHEA-AI

neutral